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Protein synthesis in rabbit reticulocytes: Characteristics of a
postribosomal supernatant factor that reverses inhibition of protein
synthesis in heme-deficient lysates and inhibition of ternary complex
(Met-tRNAfMeteeIF-2.GTP) formation by heme-regulated inhibitor*
(translational regulation/Met-tRNAfMet binding factor/eukaryotic initiation factors)
R. 0. RALSTON, A. DAS, M. GRACE, H. DAS, AND N. K. GUPTA
Department of Chemistry, The University of Nebraska, Lincoln, Nebraska 68588
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ABSTRACT During heme deficiency in reticulocyte lysates,
a translational inhibitor (heme-regulated inhibitor, HRI) that
blocks polypeptide chain initiation is activated. HRI is a protein
kinase that specifically phosphorylates the 38,000-dalton subunit
of the Met-tRNAfMet binding factor, eIF-2. Phosphorylation of
eIF-2 by HRI prevents its interaction with at least two addi-
tional factors, resulting in a net reduction in formation of ter-
nary complex (Met-tRNAfMet eIF-2.GTP) and AUG-dependent
transfer of Met-tRNAfMet to 40S ribosomal subunits. A factor
isRF) that reverses protein synthesis inhibition in heme-deficient
Iysates has been purified from reticulocyte postribosomal su-
pernatant. sRF also reverses the inhibition of ternary complexformation by HRI in a fractionated system. The ternary complex
inhibition reversal activity and the protein synthesis inhibition
reversal activity cosediment at 12.5 S upon glycerol density
gradient centrifugation, and both activities are sensitive to heat
or N-ethylmaleirmide. Purified sRF does not dephosphorylate
eIF-2 whose phosphorylation has been catalyzed by HRI, nor
does the sRF prevent the phosphorylation of eIF-2 by HRI in
a fractionated system. sRF stimulates ternary complex forma-
tion by both phosphorylated and nonphosphorylated eIF-2.
These observations suggest that the sensitivity of protein syn-
thesis to phosphorylation of eIF-2 by HRI may be modulated
by the concentration and activity of sRF.
During heme deficiency in reticulocyte lysates, protein syn-
thesis shuts off abruptly due to activation of a latent protein
synthesis inhibitor, the heme-regulated inhibitor (HRI) (9-19).
HRI is a protein kinase that specifically phosphorylates the
38,000-dalton subunit of the Met-tRNAfMet (tRNAfMet will be
abbreviated to tRNAf) binding factor, eukaryotic initiation
factor 2 (eIF-2), producing eIF-2(P) (20-24). Phosphorylation
of eIF-2 does not inhibit its activity per se but prevents its in-
teraction with at least two factors: Co-eIF-2B (or ternary
complex dissociation factor, TDF) (25, 26) and Co-eIF-2C (1,
7). Co-eIF-2B is required for AUG-dependent Met-tRNAf
binding to 40S ribosomal subunits (4). Co-eIF-2C relieves the
Mg2+ inhibition of ternary complex formation, resulting in an
apparent stimulation (1, 7). Factors similar to Co-eIF-2C have
been reported by deHaro et al. (27, 28) and Ranu and London
(29). Phosphorylation of eIF-2 by HRI thus results in a net re-
duction of ternary complex formation and loss of efficient
Met-tRNAf transfer to 40S ribosomal subunits.
The inhibition of protein synthesis in heme-deficient lysates
can be overcome by the addition of the ribosomal salt (0.5 M
KCI) wash or a partially purified preparation of eIF-2 (30-33).
We have reported (8) that this activity (protein synthesis inhi-
bition reversal factor from ribosomes, rRF) is not due to eIF-2
nor is it correlated with eIF-2 activity or concentration. rRF was
resolved from the bulk of eIF-2. Also, homogeneous eIF-2 was
inactive in reversal of protein synthesis inhibition in heme-
deficient lysates.
Another factor that reverses protein synthesis inhibition in
heme-deficient lysates has been isolated from reticulocyte
postribosomal supernatant (34-36). In this paper, we describe
further purification and characterization of this factor, protein
synthesis inhibition reversal factor from supernatant (sRF).
sRF efficiently restores the protein synthesis activity of
heme-deficient lysates to the level observed in the presence of
hemin and also reverses the inhibition of ternary complex for-
mation by HRI in a fractionated system. The sRF activities for
ternary complex inhibition reversal and for protein synthesis
inhibition reversal cosediment at 12.5 S upon glycerol density
gradient centrifugation, and both activities are sensitive to
N-ethylmaleimide and heat. sRF neither dephosphorylates
eIF-2(P) nor blocks phosphorylation of eIF-2 by HRI in a
fractionated system. sRF stimulates ternary complex formation
by both phosphorylated and nonphosphorylated eIF-2.
MATERIALS AND METHODS
Materials. The materials were obtained from the following
sources: [14C]leucine [289-355 mCi/mmol (1 Ci = 3.7 X 1010
becquerels)] from New England Nuclear; [85S]methionine (900
Ci/mmol) from Amersham; [,y-32P]ATP (2.7-3.1 Ci/mmol)
from ICN; PM-10 ultrafiltration membranes from Amicon,
Lexington, MA; GTP-agarose from Sigma. The sources of most
of the other materials used in these studies have been described
(8).
Preparations of Rabbit Reticulocyte Lysates and Assay
of Protein Synthesis. The procedures for the preparation of
reticulocytes and reticulocyte lysates and the incubation mix-
tures for protein synthesis have been described (14, 20). Protein
synthesis was assayed by the incorporation of [14C]leucine into
hot trichloroacetic acid-insoluble protein. The specific activity
Abbreviations: The present nomenclature for the peptide chain eu-
karyotic initiation factors (eIFs) (1), their past nomenclature (shown
in parentheses) (2) as used by our laboratory, and their characteristic
functions are: eIF-2 (EIF-1), Met-tRNAfMet binding factor (3, 4);
eIF-2(P), phosphorylated eIF-2 (phosphorylation catalyzed by
heme-regulated translational inhibitor); Co-eIF-2A (Co-EIF-1),
stimulates Met-tRNAfMet binding to eIF-2 (5, 6); Co-eIF-2B (EIF-2,
TDF), promotes dissociation of ternary complex at high Mg2+ (4);
Co-eIF-2C (EIF-2B), reverses Mg2+ inhibition of ternary complex
formation (7); HRI, heme-regulated translational inhibitor; rRF, ri-
bosomal salt wash factor that reverses protein synthesis inhibition in
heme-deficient lysates (8); sRF, postribosomal supernatant factor that
reverses protein synthesis inhibition in heme-deficient lysates. tRNAf,
tRNAfMet; NaDodSO4, sodium dodecyl sulfate; MalNEt, N-ethyl-
maleimide.
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of the ['4C]leucine used is shown in the figure legends. The KC1
concentration in the lysates was 80 mM in all cases. Incubation
was at 30'C for 30 min unless otherwise indicated. Three dif-
ferent reaction volumes were used (12, 25, and 50,ul) for con-
venience in particular experiments. Specific activities of
[14C]leucine and aliquot size were adjusted so that the amounts
of [14C]leucine incorporated in the aliquots were comparable
in all three systems.
Sodium Dodecyl Sulfate (NaDodSO4) Gel Electrophoresis
and Autoradiography. Electrophoresis of proteins in NaDod-
SO4 polyacrylamide gels was performed according to the
method of Laemmli (37). The gels contained 10% acrylamide
(10% acrylamide, 0.27% N,N'-methylenebisacrylamide). The
separating gels were formed as 1.5 X 100 X 150-mm slabs, with
1.5-cm stacking gels (5% acrylamide). Electrophoresis was
performed at 150 V for 31/2 hr in a Bio-Rad model 220 elec-
trophoresis apparatus. The gels were stained with Coomassie
brilliant blue. Autoradiography was performed as described
with Kodak X-Omat R film (21).
Protein Determination. Protein concentration was deter-
mined according to the method of Bradford (38) as modified
by Spector (39) with bovine serum albumin as the standard.
Preparation of sRF. The sRF was prepared as described by
Gross (35), except that 10 mM Tris-HCI, pH 7.8 was used in-
stead of Hepes, and the DEAE-cellulose column was eluted by
using 0.1 M, 0.2 M, 0.3 M, and 0.5 M KCI. The bulk of the sRF
activity eluted with the 0.2 M KCI wash. The active fractions
were pooled and concentrated by ultrafiltration. The concen-
trated sRF (1.5 ml, 14 mg/ml) was loaded on a 1.2 X 4.8-cm
GTP-agarose column equilibrated with buffer A (10 mM
Tris-HCI, pH 7.8/1 mM dithiothreitol/0.1 mM EDTA/0.1 M
KCI). The bulk of the sRF activity does not bind to the column
and elutes in the void volume. The active fractions were pooled
and concentrated by dialysis against 80-90% saturated am-
monium sulfate as described by Schreier et al. (40). The con-
centrated sRF was dissolved in buffer A containing 10% (vol/
vol) glycerol at a protein concentration of 4-8 mg/ml and stored
at -96°C.
RESULTS
The sRF was purified by using DEAE-cellulose and GTP-
agarose column chromatography. The bulk of sRF activity was
not retained on the GTP-agarose column, whereas almost all
of eIF-2 activity was bound and was later eluted by using 0.1
M GTP (Fig. 1). The GTP-agarose-purified sRF preparation
was stored at -96°C. Under this condition, the preparation
remained active for at least a month.
GTP-agarose-purified sRF efficiently reversed protein
synthesis inhibition in heme-deficient lysates (Fig. 2). The
amount of sRF giving maximum reversal (86 ,g) (Fig. 2) bound
only 0.31 pmol of [35S]Met-tRNAf in the presence of GTP in the
Millipore filtration assay. NaDodSO4 gel electrophoresis result
(data not shown) also confirmed the removal of nearly all eIF-2
from sRF by GTP-agarose chromatography.
Phosphorylation of eIF-2 by HRI inhibits its interaction with
Co-eIF-2C, resulting in a net reduction in ternary complex
formation when assayed in the presence of Mg2+ (1, 7). We
investigated the effect of sRF on inhibition of ternary complex
formation by HRI. In these experiments we used partially pu-
rified eIF-2 preparations (eIF) [fraction II (41)] that contained
Co-eIF-2C activity.
As shown in Table 1, phosphorylation of eIF-2 by HRI in-
hibited its ability to form the ternary complex. sRF stimulated
ternary complex formation by both phosphorylated and non-
phosphorylated eIF-2. This stimulation of eIF-2 activity by sRF
was observed even if sRF was added after eIF-2 had been
phosphorylated by HRI (Table 1, experiment 2).
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FIG. 1. GTP-agarose chromatography of sRF. [35S]Met-tRNAf
binding was determined with 2-iu aliquots from fractions. RF activity
was determined with 2-,ul aliquots added to 10-,ul protein synthesis
reaction mixtures. [14C]Leucine incorporation was determined in 10-JAI
aliquots. The specific activity of the [14C]leucine was 125 cpm/pmol.
This lysate incorporated 7000 cpm of [14C]leucine in the absence of
hemin and 30,000 cpm in the presence of 40 ,uM hemin. The protein
concentration of the peak fraction of sRF was 1 mg/ml.
In order to determine whether ternary complex inhibition
and protein synthesis inhibition reversal activities were due to
the same factor, sRF was analyzed by glycerol density gradient
centrifugation. Both activities sedimented (Fig. 3) at 12.5 S,
corresponding to an approximate molecular weight of 370,000.
The ternary complex inhibition reversal activity, shown here
as stimulation of ternary complex formation in the presence of
Incubation time, min
FIG. 2. Kinetics of protein synthesis in the presence of sRF.
Reversal of protein synthesis inhibition in heme-deficient lysate by
sRF. Protein synthesis was assayed in 50-Mul reaction mixtures. The
specific activity of the [14C]leucine was 170 cpm/pmol. [14C]Leucine
incorporation was determined in 10-,ul aliquots. Where indicated, the
concentration of hemin used was 40,uM.
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Table 1. Reversal of HRI inhibition of ternary complex
formation by sRF
[35S]Met-tRNAf
bound, pmol
Additions ATP -HRI +HRI
Experiment 1
eIF - 2.11 2.30
sRF - 0.51 0.49
eIF + sRF - 3.30 3.42
eIF + 2.39 1.00
sRF + 0.39 0.44
eIF + sRF + 3.08 2.95
Experiment 2
eIF + 1.75 0.94
eIF + sRF (stage I) + 2.35 2.11
eIF + sRF (stage II) + 2.25
Standard Millipore filtration assay conditions were used. The in-
cubation mixtures in Exp. 1 contained, in a total volume of 50 1A: 30
mM Tris-HCl at pH 7.8; 130mM KCl; 15 ,gg of bovine serum albumin;
3 mM dithiothreitol; 1.5 mM magnesium acetate; and, where indi-
cated, 0.2 mM ATP, 15 ,g of eIF [fraction II (41)1,0.8 ,ug of HRI, and
16 Aig of sRF. The reaction mixtures were incubated at 370C for 10 min
(stage I). Ten microliters of 2mM GTP (final concentration 0.27 mM)
and 8-10 pmol of [35S]Met-tRNAf (15 ,Al) were added and the incu-
bation was continued at 37°C for 5 min (stage II). The reaction mix-
tures were assayed by Millipore filtration as described (41). The sRF
preparation (16 ,ug) used in this experiment bound 0.3 pmol of
[35S]Met-tRNAf in the absence of GTP. The reaction conditions in
Exp. 2 were the same as above except that sRF (16 ,ug) was added at
either stage I or stage II.
HRI and ATP, correlated well with RF activity. The downward
trend of the RF activity profile was due to inhibition of protein
synthesis by increasing concentrations of glycerol. In this case
and as reported previously (8), amino acid incorporation de-
creased linearly with glycerol concentration when blank gra-
dients were used. Addition of 5 Aul of solution containing 30%
glycerol (concentration at the bottom of the gradient) lowered
['4C]leucine incorporation to approximately 60%. The amino
acid incorporation activity of gradient fractions 1-6 (Fig. 3) was
the same as the control within experimental error.
In order to investigate whether sRF contained phosphatase
activity, the effect of sRF on phosphorylation of eIF-2 by HRI
was analyzed by NaDodSO4/polyacrylamide gel electropho-
resis and autoradiography. The results are shown in Fig. 4.
Comparison of the kinetics of phosphorylation of eIF-2 in the
absence (tracks 6-8) and presence (tracks 9-11) of sRF clearly
shows that sRF did not reduce the amount of phosphorylation
Table 2. Effects of addition of sRF and Co-eIF-2C on ternary
complex formation by eIF-2(P)
[35SlMet-tRNAf
Addition bound, pmol
None 0.15
sRF (8 ,ug) 0.58
sRF (12 ,ug) 0.69
Co-eIF-2C (2 ,ug) 0.12
CoeIF-2C (5 jig) 0.21
Standard Millipore filtration assay conditions were used. The in-
cubation mixtures contained, in a total volume of 75 ,ul: 20 mM
Tris-HCl at pH 7.8; 87mM KCl; 15 ,ug of bovine serum albumin; 2mM
dithiothreitol; 1 mM magnesium acetate; 0.27 mM GTP; 8-10 pmol
of [35S]Met-tRNAf; and eIF-2(P) [prepared as described by Das et
al. (1)]. Reaction mixtures were incubated at 37°C for 5 min, then
assayed by Millipore filtration as described (1). The eIF-2(P) prep-
aration used bound 0.88 pmol of [35S]Met-tRNAf in the absence of
Mg2+.
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FIG. 3. Glycerol density gradient centrifugation of sRF. sRF (0.9
mg, 100 gl) was centrifuged on a glycerol density gradient as described
(8). Protein standards were run in parallel. Amino acid incorporation
decreased linearly with glycerol concentration when blank gradients
were used. Reversal of ternary complex inhibition (stimulation of
[35S]Met-tRNAf binding in the presence of HRI and ATP) was as-
sayed as described for Table 1, using 10-,ul aliquots of gradient frac-
tions. RF activity was determined in 5-,l aliquots added to 20-,ul
protein synthesis reaction mixtures. Addition of 5 ,l of solution
containing 30% (vol/vol) glycerol (concentration at the bottom of the
gradient) lowered [14C]leucine incorporation to approximately 60%.
The specific activity of the [14C]leucine was 85 cpm/pmol. tl4C]Leu-
cine incorporation was determined in 20-,ul aliquots. The gradients
were scanned at 280 nm in an ISCO UA-5 absorbance monitor con-
nected to an ISCO density gradient fractionator. The protein con-
centrations of the sRF gradient fractions were also determined.
Sedimentation coefficients and molecular weights for the standards
were taken from ref. 42. The molecular weight of sRF was approxi-
mated by plotting Mr of the standards vs. depth of sedimentation.
of the 38,000-dalton subunit of eIF-2. When eIF-2 was phos-
phorylated by preincubation with HRI, the extent of phos-
phorylation was not affected by addition of sRF (tracks 12-14).
When HRI was preincubated with sRF, its ability to phos-
phorylate eIF-2 was unaffected (tracks 15-17). These results
clearly demonstrate that sRF did not dephosphorylate eIF-2(P)
or block phosphorylation of eIF-2 by HRI.
In another experiment, the effects of sRF and Co-eIF-2C on
ternary complex formation by purified eIF-2(P) were com-
pared. The results are shown in Table 2. As in the case of eIF-2,
ternary complex formation by eIF-2(P) was strongly inhibited
by Mg2+. sRF stimulated ternary complex formation by eIF-
2(P). As expected, Co-eIF-2C did not stimulate ternary complex
formation by eIF-2(P) even at saturating concentrations (1).
These results clearly demonstrate that reversal of ternary
complex inhibition of sRF was not due to Co-eIF-2C.
Another factor, Co-eIF-2A, stimulates ternary complex
formation by both eIF-2 and eIF-2(P). The molecular weight
of the purified factor is 25,000. However, a heavy form of this
Proc. Natl. Acad. Sci. USA 76 (1979) 5493
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FIG. 4. Phosphorylation of eIF-2 in the presence of sRF. The
reaction mixtures (25 ,ul) contained the same components as the
[35S]Met-tRNAf binding assay mixtures described in Table 1, except
that highly purified eIF-2 was used instead of partially purified eIF-2.
Incubation was at 370C for the time indicated. The specific activity
of the [y-32P]ATP used was 2400 cpm/pmol. The reaction mixture
was subjected to NaDodSO41polyacrylamide gel electrophoresis and
autoradiography; exposure was for 6 hr. Track 1, HRI (0.4 Mg), 10 min;
track 2, eIF-2 (0.4 Mg), 10 min; track 3, sRF (8 Mug), 10 min; track 4,
eIF-2 + sRF, 10 min; track 5, HRI + sRF, 10 min; tracks 6-8, HRI +
eIF-2, 2, 5, and 10 min, respectively; tracks 9-11, HRI + eIF-2 + sRF,
2, 5, and 10 min, respectively; tracks 12-14, HRI + eIF-2, 10 min,
followed by addition of sRF and further incubation for 2, 5, and 10
min, respectively; tracks 15-17, HRI + sRF, 10 min, followed by ad-
dition of eIF-2 and further incubation for 2, 5, and 10 min, respec-
tively.
factor (Mr 200,000) has also been observed (6). Co-eIF-2A is
stable to heat and N-ethylmaleimide (MalNEt). In order to
determine whether stimulation by Co-eIF-2A present in sRF
was responsible for reversing ternary complex inhibition by
HRI, sRF was treated with heat or MalNEt and its ability to
reverse ternary complex inhibition was determined. Table 3
clearly shows that the ability of sRF to reverse ternary complex
inhibition was abolished by heat or MalNEt. In adddition, the
RF activity of sRF was completely abolished by similar heat
or MalNEt treatment (data not shown). Reversal of inhibition
of ternary complex formation by sRF was not due to Co-eIF-
2A.
DISCUSSION
The results presented here clearly demonstrate that the su-
pernatant factor, sRF, that reverses inhibition of protein syn-
thesis in heme-deficient lysates also reverses inhibition of ter-
nary complex formation by HRI. sRF stimulates ternary
complex formation under experimental conditions in which
eIF-2 is phosphorylated by HRI. sRF also stimulates ternary
complex formation by purified eIF-2(P) as well as by the non-
phosphorylated form. This stimulation is not due to dephos-
Table 3. Effects of MalNEt addition and heat on sRF activity
[35S]Met-tRNAf bound, pmol
Additions -HRI -ATP +HRI +ATP
eIF 1.4 0.7
eIF + sRF 2.0 1.6
eIF + heated sRF 1.5 0.7
eOF + MalNEt-treated sRF 1.6 0.6
Standard Millipore filtration assay conditions described for Table
1 were used. Where indicated, sRF was heated at 55°C for 5 min or
incubated at 37°C in the presence of 5 mM MalNEt for 5 min. The
excess MalNEt was neutralized by addition of dithiothreitol at a final
concentration of 10 mM. The heated and MalNEt-treated sRF
preparations were inactive in reversing protein synthesis inhibition
in heme-deficient lysates.
phorylation of eIF-2(P) by sRF. Also, sRF does not prevent
phosphorylation of eIF-2 by HRI. These results suggest that sRF
can promote protein synthesis even in the presence of inhibitory
concentrations of HRI, with eIF-2(P) as an active initiation
factor.
The supernatant factor sRF described in this paper appears
similar to another factor that we now term rRF. rRF is purified
from the ribosomal 0.5 M KCI wash and reverses protein syn-
thesis inhibition in heme-deficient lysates in a manner similar
to sRF (8). rRF has been purified from the bulk of eIF-2 activity
by using GTP-agarose chromatography, and there are indica-
tions that rRF also reverses ternary complex inhibition by HRI.
Like sRF, rRF sediments at 12-13 S upon glycerol density
gradient centrifugation.
These observations raise important questions regarding the
basic mechanism of peptide chain initiation and the regulation
of protein synthesis in eukaryotic cells. Despite numerous re-
ports from several laboratories, the detailed mechanism of
peptide chain initiation and characteristics of the protein factors
involved are not clearly understood. The first step in peptide
chain initiation is the formation of a ternary complex, Met-
tRNAf eIF-2-GTP. Reports from our laboratory (4-7) and
elsewhere (27-29) indicate that ternary complex formation by
eIF-2 is regulated by several protein factors, although the
precise roles of these factors in protein synthesis initiation are
not known. Formation of the ternary complex by eIF-2 is
stongly affected by Mg2+. Ternary complex formation by ho-
mogeneous preparations of eIF-2 is optimal in the absence of
Mg2+ and is strongly inhibited by Mg2+. However, once the
ternary complex is formed, the complex is stable to further
addition of Mg2+. Co-eIF-2C relieves Mg2+ inhibition of ter-
nary complex formation, producing an apparent effect of
stimulation (7). This factor would, therefore, appear to be re-
quired for protein synthesis initiation at physiological Mg2+
concentrations.
HRI phosphorylates the 38,000-dalton subunit of eIF-2.
Ternary complex formation by eIF-2(P) is not stimulated by
Co-eIF-2C (1, 7, 27-29). It has been suggested that loss of in-
teraction of eIF-2(P) with Co-eIF-2C is responsible for the in-
hibition of ternary complex formation by HRI.
However, the precise roles of different factors in the for-
mation of initiation complexes with 40S ribosomal subunits are
not known. A high molecular weight factor, Co-eIF-2B, pro-
motes dissociation of the ternary complex in the presence of
high Mg2+ concentration (5 mM) and low temperature (00C).
In the presence of eIF-2, Co-eIF-2B preparations give 3-fold
stimulation of Met-tRNAf binding to 40S ribosomes (4). Pre-
sumably, some component in this high molecular weight protein
complex [Co-eIF-2B is composed of multiple (16-20) poly-
peptides and has molecular weight of approximately 450,000]
is necessary for 40S initiation complex formation. However, the
relationship of this component to the factor that promotes dis-
sociation of the ternary complex is not clear. The ternary
complex formed with eIF-2(P) is not dissociated by Co-eIF-2B
and is also inactive in 40S initiation complex formation. This
observation suggests that the ternary complex dissociation ac-
tivity in Co-eIF-2B may be involved in 40S initiation complex
formation, possibly releasing eIF-2 after Met-tRNAf is bound
to the 40S ribosomal subunit.
The role of Co-eIF-2C in 40S initiation complex formation
is not clear. Co-eIF-2C presumably restores the active confor-
mation of eIF-2 in the presence of Mg2+ and may play an im-
portant role in peptide chain initiation. An alternative possibility
is that Mg2+ alters the conformation of Met-tRNAf such that
an additional factor (Co-eIF-2C) is required for Met-tRNAf
binding to eIF-2. However, it is conceivable that other factors
Biochemistry: Ralston et al.
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besides Co-eIF-2C may perform similar functions. Possibly, sRF
is such a factor.
sRF reverses protein synthesis inhibition in heme-deficient
lysates and also reverses ternary complex inhibition by HRI.
sRF does not dephosphorylate eIF-2(P) or protect eIF-2 from
phosphorylation by HRI. sRF stimulates ternary complex for-
mation by both purified eIF-2 and eIF-2(P). The characteristics
of stimulation of ternary complex formation by sRF are thus
clearly different from those observed with Co-eIF-2C. Also,
unlike sRF, Co-eIF-2C does not reverse protein synthesis in-
hibition in heme-deficient lysates. The sRF preparation contains
some Co-eIF-2B activity. It is possible that sRF alters the con-
formation of eTF-2(P) so that it is recognized by Co-eIF-2B and
is also active in 40S initiation complex formation.
The results presented in this paper provide another example
of complex regulation of protein synthesis initiation in eukar-
yotic cells. During heme deficiency, protein synthesis in re-
ticulocyte lysate, is inhibited due to activation of HRI. However,
a careful analysis of the data will reveal that a low but detect-
able rate of protein synthesis continues over a prolonged period
in these heme-deficient lysates. It is conceivable that sRF ac-
tivity in these lysates is responsible for the continued low rate
of protein synthesis in the presence of inhibitory concentrations
of HRI. The presence of eIF-2(P) phosphatase activity in re-
ticulocyte lysate has also been reported (43) and may provide
yet another mechanism of reversal of protein synthesis inhibi-
tion in heme-deficient lysates. However, sRF does not contain
any eIF-2(P) phosphatase activity, and, also, sRF stimulates
ternary complex formation even when eIF-2 is phosphorylated.
These observations suggest that the sensitivity of protein syn-
thesis to phosphorylation of eIF-2 by HRI may be modulated
by the concentration and activity of sRF.
In conclusion, we propose a dual mechanism for regulation
of protein synthesis initiation in eukaryotic cells. Both Co-
eIF-2C and sRF promote ternary complex formation by eIF-2
at physiological Mg2+ concentrations. We suggest that, in
rapidly growing cells, Co-eIF-2C may represent the dominant
factor. In such cases, protein synthesis would be expected to be
highly sensitive to eIF-2 kinases, as is observed in reticulocyte
lysates. In resting cells in which eIF-2 kinases may be active,
we suggest that the presence of sRF may ensure a continued low
rate of protein synthesis necessary for cell survival.
Note Added in Proof. After we submitted our manuscript for review,
we noted that Benne et al. [Benne, R., Amsez, H., Goumans, H. &
Voorma, H. (1979) XI International Congress of Biochemistry, p. 129
(abstr.)] have also observed that a postribosomal supernatant factor,
similar to sRF, that reverses protein synthesis inhibition in heme-de-
ficient reticulocytes does not dephosphorylate eIF(P) or prevent HRI
phosphorylation of eIF-2.
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